Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Study Planning With FDA, EMA To Be More Closely Aligned

Executive Summary

Beginning in January, FDA will require initial pediatric study plans be submitted after the end-of-Phase II meeting, rather than well into Phase III, which is expected to improve planning and expand coordination with EMA.

You may also be interested in...

Priority Review Vouchers For Pediatric Rare Disease: Will Popularity Force A Quick Halt?

Based on designations, FDA already could have enough products in the pipeline to trigger the mandatory program stop and assessment.

Pediatric Study Waiver, Deferral Determinations Could Harm Approvals, Firms Tell FDA

Comments on draft guidance say agency’s belated decisions on requests for waivers or deferrals of pediatric studies could lead to “refuse to file” determinations; FDA has missed statutory deadline to promulgate regulations on pediatric study plans.

Should FDA Be Forced To Consider Development Time And Cost?

Venture capitalist suggests the agency should keep both issues in mind when it orders a sponsor to conduct more trials or submit additional data in order to bring down the cost of drug development.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts